|Articles|December 17, 2013
- Melanoma (Issue 1)
- Volume 1
- Issue 1
The Challenges of Treating Metastatic Melanoma With BRAF Inhibitor Monotherapy
Author(s)Adil Daud, MD
Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.
Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.
At the Society for Melanoma Research 2013 Congress, Daud presented an overall survival update for BRF113220 part C, a phase II three-arm randomized study of dabrafenib alone versus combination of dabrafenib and trametinib in patients with BRAF V600 mutation-positive metastatic melanoma.
Read about the treatment of melanoma withcombinations and immunotherapies
Articles in this issue
almost 12 years ago
Two BRAF Fusions Discovered in Some Pan-Negative Melanomasalmost 12 years ago
Understanding the Biologic Pathways in Basal Cell Carcinomaalmost 12 years ago
Advances in Metastatic Melanomaalmost 12 years ago
Targeted Therapies in Basal Cell Carcinomaalmost 12 years ago
The Outlook for BRAF Inhibitors in Melanomaalmost 12 years ago
The Treatment of Melanoma With Emerging Targeted TherapiesRelated Content
Advertisement
